Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 20;14(2):e22404.
doi: 10.7759/cureus.22404. eCollection 2022 Feb.

Efficacy of Oral Famotidine in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2

Suraksha Pahwani  1 , Mahesh Kumar  1 , Fnu Aperna  1 , Mehak Gul  1 , Darshan Lal  2 , Fnu Rakesh  2 , Muhammad Raffey Shabbir  3 , Amber Rizwan  4
Affiliations

Efficacy of Oral Famotidine in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2

Suraksha Pahwani et al. Cureus. .

Abstract

Introduction The clinical benefit of famotidine has been observed in the management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, its use in the management of SARS-CoV-2 is intriguing and not well established yet. In this study, we aimed to determine the role of famotidine as adjuvant therapy in improving the outcome of patients hospitalized with coronavirus disease-2019 (COVID-19). Methods This two-arm open-label randomized interventional study was conducted in the COVID-19 unit of a tertiary care hospital in Pakistan from December 2020 to September 2021. Patients between the ages of 18 to 65 years, hospitalized with COVID-19 infection, were enrolled in the study. Participants were randomized into two groups. The intervention group received 40 mg oral famotidine daily in addition to the standard care and the control group received standard care as per national guidelines for the treatment of COVID-19 in Pakistan. Results Patients admitted with COVID-19 who received famotidine took comparatively fewer days to become symptom-free (8.5 ± 1.7 vs. 9.4 ± 1.9 days, p-value: <0.001) and spent fewer days in hospital (8.6 ± 1.6 vs. 10.3 ± 2.2 days; p-value: <0.0001). However, the overall difference in the need for mechanical ventilation and mortality between the interventional arm and placebo was not significant. Conclusion In this study, adding famotidine to standard treatment of COVID-19 was associated with faster clinical recovery and shorter stay in the hospital. However, there was no difference in the need for mechanical ventilation, need for intensive care unit, and overall mortality. Further large-scale studies are needed to understand the role of famotidine in COVID-19 and its mechanism of action in patients with COVID-19.

Keywords: anti reflux; covid-19; famotidine; management; pakistan.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Similar articles

See all similar articles

Cited by

References

    1. SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options. Chakraborty C, Sharma AR, Sharma G, Bhattacharya M, Lee SS. Eur Rev Med Pharmacol Sci. 2020;24:4016–4026. - PubMed
    1. Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients. Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Am J Roentgenol. 2020;215:87–93. - PubMed
    1. Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-PCR assay validated in vitro and with clinical specimens. Chan JF, Yip CC, To KK, et al. J Clin Microbiol. 2020;58:0–20. - PMC - PubMed
    1. Clinical progression of patients with COVID-19 in Shanghai, China. Chen J, Qi T, Liu L, et al. J Infect. 2020;80:0–6. - PMC - PubMed
    1. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Huang C, Wang Y, Li X, et al. Lancet. 2020;395:497–506. - PMC - PubMed

LinkOut - more resources